<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04110418</url>
  </required_header>
  <id_info>
    <org_study_id>FWA000017586</org_study_id>
    <nct_id>NCT04110418</nct_id>
  </id_info>
  <brief_title>Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate</brief_title>
  <official_title>Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, prospective study comparing methylene blue versus terlipressin in treatment of
      catecholamines resistant shock in preterm neonate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be an un-blinded, Phase 2, randomized, 1:1, prospective trial comparing
      methylene blue versus terlipressin in treatment of preterm neonate with catecholamines
      resistant septic shock the outcome as regard elevation of mean arterial blood pressure will
      be measured within 72 hours
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Anticipated">February 19, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to assess the efficancy of each intervention in improving hemodymaic status: time taken to reach adequate mean blood pressure</measure>
    <time_frame>24hours</time_frame>
    <description>The time taken to reach adequate mean blood pressure
Reduction in the dosage of the standard inotropic support</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess the effect of intervention on survival</measure>
    <time_frame>4 days</time_frame>
    <description>mortality rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Neonatal Sepsis</condition>
  <condition>Refractory Shock</condition>
  <arm_group>
    <arm_group_label>Methylene Blue group (Group MB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylene Blue is supplied in 1 ml or 10 mL single-dose ampules. Each 1 mL ampule contains 10 mg of methylene blue as a clear dark blue solution
Any unused product or waste material should be disposed of in accordance with local practice,
For administration to be diluted before use in a solution of 50 mL 5% Dextrose in Water (D5W) in order to avoid local pain, particularly in the paediatric population. Use the diluted solution immediately after preparation.
Do not mix with sodium chloride 9 mg/mL (0.9%) solution for injection, because it has been demonstrated that chloride reduces the solubility of methylene blue.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Terlipressin Group (Group TP )</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The active substance is terlipressin acetate. Each ampoule contains
1 mg of terlipressin acetate in 8.5 ml solution for injection. This is equivalent to 0.12 mg terlipressin acetate per ml.
The powder is to be dissolved in the enclosed solvent and slowly administered intravenously. Further dilution up to 10 ml with sterile isotonic sodium chloride solution is possible.
Store in a refrigerator at 2-8˚C.
Keep the ampoules in the outer carton in order to protect from light</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)
Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h</description>
    <arm_group_label>Methylene Blue group (Group MB)</arm_group_label>
    <arm_group_label>Terlipressin Group (Group TP )</arm_group_label>
    <other_name>terlipressin acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Neonate with Gestational age at birth ≤ 36weeks

        Inclusion Criteria:

          -  diagnosis of Septic shock according to clinical sepsis score of Tollner and
             Hematologic Scoring System of Rodwell

          -  Refractory septic shock defined as hypotension although adequate fluid resuscitate and
             high dose vasopressor(NE &gt;0.5 mcg/kg/min)

          -  consent form

        Exclusion Criteria:

          -  known case of G6pd deficiency

          -  Hx of drug allergy MB, NE, terlipressin

          -  Patients with severely impaired renal function.

          -  History of maternal drug intake of selective serotonin reuptake inhibitors,and
             Serotonin-Norepinephrine Reuptake Inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>rabab allam, physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>ain shams university faculty of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>rabab allam, physician</last_name>
    <phone>01119069425</phone>
    <phone_ext>202</phone_ext>
    <email>dr_rabab_asu@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neonatal Intensive Care Units (NICUs), Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Abbasia</state>
        <zip>1234</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>rabab allam, physician</last_name>
      <phone>01119069425</phone>
      <phone_ext>202</phone_ext>
      <email>dr_rabab_asu@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Rabab Gameel Abd EL hamid allam</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <keyword>methylene blue</keyword>
  <keyword>terlipressin</keyword>
  <keyword>septic shock</keyword>
  <keyword>preterm neonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

